GSK plans five Phase 3 studies for gynecological cancer ADC from Hansoh
葛兰素史克计划开展5项针对妇科肿瘤的ADC三期研究，药物来自翰森制药

GSK shared early promising data Sunday from the antibody-drug conjugate it licensed from its Chinese partner Hansoh Pharma. The UK company now plans to start studying the asset in five Phase 3 studies in gynecological cancers.
葛兰素史克周日分享了其从manbetx3.0 合作伙伴翰森制药引进的抗体药物偶联物的早期令人鼓舞的数据。该英国公司现计划在妇科肿瘤领域开展五项三期研究，以评估这一资产。